Capital Com MENA Securities Trading LLC is regulated by the Capital Market Authority.
Open platformOpen platform

Incyte Q3 adjusted loss per share beats estimates

By Reuters News


Overview

  • U.S. biopharmaceutical firm's Q3 revenue rose 14% yr/yr, driven by growth in core products

  • Q3 adjusted loss per share beat analyst expectations

  • Company raised full-year 2026 net sales guidance for Opzelura, Hematology and Oncology, and total net sales


Outlook

  • Incyte raises 2026 total net sales guidance to $5.21-$5.3 bln from $5.13-$5.26 bln

  • Company lifts 2026 Opzelura net sales forecast to $1.1-$1.12 bln from $1.05-$1.1 bln

  • 2026 Hematology and Oncology net sales outlook increased to $890-$910 mln from $860-$890 mln


Result Drivers

  • OPZELURA DEMAND AND PRICING - Co said Q3 Opzelura sales rose due to higher patient demand in atopic dermatitis and vitiligo and improved net pricing

  • HEMATOLOGY AND ONCOLOGY DEMAND - Co said Q3 Hematology and Oncology sales grew on higher demand for Niktimvo, Zynyz and Monjuvi/Minjuvi

  • JAKAFI DEMAND - Co said Q3 Jakafi sales rose due to higher paid demand and growth across all indications


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Adjusted Loss Per Share

Beat

$3.60

$3.85 (17 Analysts)

Q3 Loss Per Share

$3.86

Q3 Adjusted Operating Income

Beat

-$629.72 mln

-$786.67 mln (13 Analysts)


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", 16 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy"

  • Wall Street's median 12-month price target for Incyte Corp is $130.00, about 11.2% above its October 28 closing price of $116.87

  • The stock recently traded at 15 times the next 12-month earnings vs. a P/E of 14 three months ago


Reuters Recommended Reads

  • Oct 28 - Biogen tops quarterly estimates on rare-disease drug strength

  • Oct 29 - Eli Lilly lifts revenue outlook on weight-loss drug sales, trims profit view on deal charges

  • Oct 28 - GSK tops third-quarter estimates as new medicines drive growth, keeps outlook


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.